1-3 of 3
Davide Melisi
Close
Sort by
Journal Articles

A Phase 2 Study of Futibatinib (TAS-120) in Patients with Myeloid or Lymphoid Neoplasms Harboring Fibroblast Growth Factor Receptor ( FGFR) 1 Rearrangements

Jean-Jacques Kiladjian, Kohei Shitara, Lee Stephen Rosen, Sun Young Rha, Aiwu He, Do-Youn Oh, Davide Melisi, Satoru Iwasa, Yixing Jiang, Sherry Liu, Osamu Takahashi, Vincent Ribrag
Journal: Blood
Blood (2021) 138 (Supplement 1): 3656.
https://doi.org/10.1182/blood-2021-150630
Published: 2021
Journal Articles

Pathologic angiogenesis in the bone marrow of humanized sickle cell mice is reversed by blood transfusion

Shin-Young Park, Alessandro Matte, Yookyung Jung, Jina Ryu, Wilson Babu Anand, Eun-Young Han, Min Liu, Carmine Carbone, Davide Melisi, Takashi Nagasawa, Joseph J. Locascio, Charles P. Lin, Leslie E. Silberstein, Lucia De Franceschi
Journal: Blood
Blood (2020) 135 (23): 2071–2084.
https://doi.org/10.1182/blood.2019002227
Published: 2020
Includes: Multimedia, Supplemental data
Journal Articles

The Vasculopathy in the Bone Marrow Microenvironment of Humanized Sickle Cell Mice Is Reversible By Blood Transfusion

Shin-Young Park, PhD, Alessandro Mattè, BSc,PhD, Yookyung Jung, PhD, Jina Ryu, PhD, Wilson Anand, Eun Young Anna Han, B.S., Min Liu, M.S., Carmine Carbone, Davide Melisi, Takashi Nagasawa, Charles Lin, PhD, Leslie E. Silberstein, MD, Lucia De Franceschi, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2256.
https://doi.org/10.1182/blood-2019-123532
Published: 2019